Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Economic Evaluation of Endovascular Treatment for Acute Ischemic Stroke

Title: Economic Evaluation of Endovascular Treatment for Acute Ischemic Stroke
Authors: Van Den Berg, Lucie A.; Berkhemer, Olvert A.; Fransen, Puck S.S.; Beumer, Debbie; Lingsma, Hester; Majoie, Charles B.M.; Dippel, Diederik W.J.; Van Der Lugt, Aad; Van Oostenbrugge, Robert J.; Van Zwam, Wim H.; Roos, Yvo B.; Dijkgraaf, Marcel G.W.
Source: Van Den Berg, L A, Berkhemer, O A, Fransen, P S S, Beumer, D, Lingsma, H, Majoie, C B M, Dippel, D W J, Van Der Lugt, A, Van Oostenbrugge, R J, Van Zwam, W H, Roos, Y B & Dijkgraaf, M G W 2022, 'Economic Evaluation of Endovascular Treatment for Acute Ischemic Stroke', Stroke, vol. 29, no. 2, pp. 968-975. https://doi.org/10.1161/strokeaha.121.034599
Publication Year: 2022
Subject Terms: /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being; name=SDG 3 - Good Health and Well-being
Description: Background and Purpose: Endovascular treatment for acute ischemic stroke has been proven clinically effective, but evidence of the cost-effectiveness based on real-world data is scarce. The aim of this study was to assess whether endovascular therapy plus usual care is cost-effective in comparison to usual care alone in acute ischemic stroke patients. Methods: An economic evaluation was performed from a societal perspective with a 2-year time horizon. Empirical data on health outcomes and the use of resources following endovascular treatment were gathered parallel to the MR CLEAN trial (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) and its 2-year follow-up study. Incremental cost-effectiveness ratios were calculated as the extra costs per additional patient with functional independence (modified Rankin Scale score 0-2) and the extra cost per quality-adjusted life year gained. Results: The mean costs per patient in the intervention group were $126 494 versus $143 331 in the control group (mean difference, -$16 839 [95% CI, -$38 113 to $5456]). Compared with patients in the control group, more patients in the intervention group achieved functional independence, 37.2% versus 23.9% (absolute difference, 13.3% [95% CI, 4.0%-22.0%]) and they generated more quality-adjusted life years, 0.99 versus 0.83 (mean difference of 0.16 [95% CI, 0.04-0.29]). Endovascular treatment dominated standard treatment with $18 233 saved per extra patient with a good outcome and $105 869 saved per additional quality-adjusted life year. Conclusions: Endovascular treatment added to usual care is clinically effective, and cost saving in comparison to usual care alone in patients with acute ischemic stroke. Registration: URL: https://www.trialregister.nl/trial/695; Unique identifier: NL695. URL: https://www.isrctn.com; Unique identifier: ISRCTN10888758.
Document Type: article in journal/newspaper
File Description: application/pdf
Language: English
ISSN: 0039-2499; 1524-4628
Relation: info:eu-repo/semantics/altIdentifier/pmid/34645287; info:eu-repo/semantics/altIdentifier/pissn/0039-2499; info:eu-repo/semantics/altIdentifier/eissn/1524-4628
DOI: 10.1161/strokeaha.121.034599
Availability: https://pure.eur.nl/en/publications/7847b3b3-b0b3-4545-af57-74411f7361c1; https://doi.org/10.1161/strokeaha.121.034599; https://pure.eur.nl/ws/files/82630375/STROKEAHA.121.034599.pdf; https://www.scopus.com/pages/publications/85125553730
Rights: info:eu-repo/semantics/openAccess
Accession Number: edsbas.B894940B
Database: BASE